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Abstract
Background: Tumor escape mechanisms mediated in the tumor microenvironment can significantly reduce the
capacity of the anti-tumor function of the immune system. TIE2-expressing monocytes (TEMs), related
angiopoietins, and tumor necrosis are considered to have a key role in this process. We aimed to investigate the
abundance and clinical significance of these biomarkers in hepatocellular carcinoma (HCC).
Methods: In this retrospective study, 58 HCC patients received surgery with a curative intent. The abundance of
TEMs, angiopoietin-1 and -2 were detected in tumor specimens of the HCC patients (n = 58), and together with the
occurrence of histologic tumor necrosis, were associated with established clinicopathological characteristics and
survival.
Results: Patients with HCC characterized by necrosis and TEMs revealed reduced both overall survival and
recurrence-free survival (all p < 0.05). Angiopoietins and TEMs were associated with metastatic and recurrent HCC.
Furthermore, the formation of histologic tumor necrosis was associated with advanced tumor stage and density of
TEMs (all p < 0.05).
Conclusions: Histologic tumor necrosis, TEMs, and related angiopoietins were associated with multiple HCC
parameters and patient survival. The tumor necrosis–TEM–angiopoietin axis may offer a novel diagnostic modality
to predict patient outcome after surgery for HCC.
Keywords: Hepatocellular carcinoma, Tumor-infiltrating macrophages, TIE2-expressing monocytes, Tumor necrosis,
Angiopoietins, Angiogenesis, Prognosis
Background
Liver cirrhosis is an established risk factor for HCC.
However, HCC also arises de novo in non-cirrhotic
livers in approximately 20% of all cases, with host in-
flammatory responses having a key importance in
hepatocarcinogenesis [1–3]. There is a rising clinical
interest in patients with de novo HCC, because this sub-
group commonly presents at an advanced stage, as sur-
veillance is usually not performed in patients without
liver disease. Tumor growth in these non-cirrhotic pa-
tients is clinically silent in its early stages because of the
lack of symptoms and compensated hepatic function.
On the other hand, the importance of non-alcoholic
steatohepatitis (NASH) in driving the process of hepato-
carcinogenesis has been recently recognized and put into
a causal context with de novo HCC [4]. Of note, NASH-
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driven hepatocarcinogenesis is mechanistically involved
in the process of necrosis formation in the tumor micro-
environment, and the latter has also been related to en-
hanced infiltration with immune-competent cells [5–9].
Furthermore, experimental studies reported on novel an-
giogenic pathways playing a key role in de novo or
NASH-driven hepatocarcinogenesis, implicating the
complex immunologic mechanisms involved in cancer
progression [10–13].
The significance of complex angiogenic properties of the
tumor microenvironment in HCC has come to the fore in
recent years. Tumor angiogenesis has been validated as an
attractive therapeutic target in the process of hepatocarci-
nogenesis, mainly in clinical trials targeting the vascular
endothelial growth factor (VEGF) pathway [14]. However,
a deeper insight into the biology of solid cancer reveals that
the host cellular immune competence in the tumor micro-
environment is mechanistically intertwined with angiogen-
esis and necrosis formation, and the blockade of only one
functional pathway does not reach the desired long-term
efficacy in cancer patients. Recently, the angiopoietin
family of ligands, angiopoietin-1 and -2, has been demon-
strated to selectively activate the endothelial cell membrane
receptor tyrosine kinase TIE2 and to espouse tumor
progression [15, 16]. In the scope of tumor angiogenesis
and metastasis, this angiopoietin axis-TIE growth factor
receptor pathway represents the key regulator of patho-
logical vascular permeability and remodeling, and its
pharmacological blockade is in clinical development in on-
cologic settings [14]. In this scenario, the role of novel
angiomodulatory monocytes/macrophages subsets in hepa-
tocarcinogenesis is vastly unknown. Angiogenic immune–
competent cells represent a unique subpopulation of
tumor-infiltrating bone marrow-derived myeloid cells,
which differ from the classical tumor-associated macro-
phages (TAMs) [17]. These cellular effectors have immense
angiogenic potential, express functionally active TIE2-
expressing macrophages (TEMs) and directly respond to
angiopoietin activity [18]. Interestingly, the tissue-
infiltrating fraction of TEMs, which promotes angiogenesis
and carcinogenesis, is localized only in the tumor micro-
environment and not in healthy tissues [17, 18]. In line
with this, our data demonstrated significant influence of
TEMs on patient outcome in other cancer types [19–21].
Thus, the study of TEMs in HCC may identify attractive
targets for immunologic checkpoint inhibition.
In rapidly growing tumors, the formation of necrosis
can be attributed to the relative hypoperfusion in the
vicinity of the tumor. However, novel scientific results
demonstrate that the nature of necrosis formation in the
vicinity of the tumor is much more complex, as its oc-
currence is functionally mediated by infiltrating mono-
cytes/macrophages and delineated its role as a
prognosticator of aggressiveness in primary solid tumors
[22–24]. The presence of tumor necrosis in HCC may
adequately characterize the tumor biology and provide
additional beneficial prognostic information. Further-
more, we previously demonstrated the importance of
histologic tumor necrosis and its relation to monocytes/
macrophages in poorly vascularized human cholangio-
carcinoma [25, 26]. However, HCC is in most cases a
highly vascularized tumor [27]. Therefore, formation of
necrosis might also be a typical feature of subsets of
HCC. However, early stage and recurrence of HCC are
difficult to detect by non-invasive imaging, and alpha-
fetoprotein (AFP) as a surveillance biomarker has been
removed from present guidelines because of its low sen-
sitivity and specificity [28]. Novel biomarkers for the
management and prognosis of HCC patients are needed,
and thus, in the current work, we focused on the poten-
tial of tumor necrosis to be facilitated by immunological
components of the tumor microenvironment (i.e., invad-
ing monocytes/macrophages).
Patients with de novo HCC are at enhanced risk for
adverse disease outcome. Intriguingly, despite tumor ne-
crosis induced by impaired tissue oxygen delivery, which
is generally due to a compromised blood supply to can-
cerous tissue, recent studies also revealed that histologic
tumor necrosis was associated with high levels of angio-
genesis and increased inflammation in the tumor micro-
environment [29, 30]. Interestingly, a strong association
between liver steatosis and formation of tumor necrosis
in de novo HCC in non-cirrhotic livers has been recently
revealed [5]. Thus, possible immunologic coherence
comprising tumor-infiltrating angiogenic monocytes/
macrophages, associated molecular factors of angiogen-
esis and formation and extent of tumor necrosis could
effectively characterize HCC patients. Recently, our
group reported on the clinicopathologic characteristics
of patients with de novo HCC and the clinical signifi-
cance of tumor-infiltrating classical monocytes and lym-
phocytes in this hepatic pathology [31]. Insofar, the
present work aimed to investigate the angiopoietin axis,
related angiogenic TEMs, and tumor necrosis in de novo
HCC in non-cirrhotic patients, and thus, deliver a dee-
per insight concerning the importance of novel im-
munologic biomarkers, which may help improve the
personal risk and prognosis stratifications by defining
subgroups of patients with beneficial or deleterious
tumor characteristics.
Methods
Patients and tumor samples
The Institutional Ethics Committee approved the con-
duction of this study (no. 234-14-14072014). Patients
(n = 58) with histopathologically confirmed HCC, who
received a major hepatectomy with a curative intent,
were included in our retrospective study (Additional
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file 3). HCC recurrence was diagnosed by a triphasic
computed tomography (CT) scan and/or a magnetic res-
onance imaging (MRI) with a liver-specific contrast
medium. We also routinely performed AFP serology.
However, hepatocarcinogenesis is, in many cases, AFP
silent [32]. Therefore, in our work, AFP negativity was
not considered a reliable tool to exclude recurrent dis-
ease. In addition, in case of suspected tumor recurrence,
CT and MRI were routinely conducted. None of the
HCC patients in our study had liver cirrhosis, history of
viral hepatitis, or was subjected to neoadjuvant radio-
and/or chemotherapy before tumor resection. The
complete inclusion and exclusion criteria of our study
are described in the Additional file 3. Paraffin-embedded
tissue blocks containing a representative HCC sample
were retrieved from the archives of the Institute of Path-
ology. Histological assessment of frequencies of cellular
infiltrates and angiopoietins and the presence of tumor
necrosis in the HCC specimens was carried out by two
investigators (KD and GA), with training in histopath-
ology, and an independent pathologist (KS), without
knowledge of the patient outcome or the corresponding
clinicopathological characteristics.
Immunohistology and quantification of TIE2-expressing
monocytes and angiopoietins
Protocols for immunohistology and density quantifica-
tion of cellular infiltrates were carried out as described
[6–8]. Briefly, tissue TEMs were double immunostained
for CD14 and TIE2, and antibodies for angiopoietin-1
and -2 were used to evaluate their abundance. The
tumor-infiltrating front (TIF) and tumor central area
(TCA) of the HCC specimens were analyzed separately.
Cellular infiltrates and angiopoietin-positive staining
were referred to as negative/absent in up to 5% positive
cells (0–5% positive cells, score 0) and positive/present
(> 5% positive cells, score 1). Next, patients were
assigned to two different groups (negative or positive for
TEMs, and angiopoietin-1- or -2-positive tumor cells).
The Additional file 3 provides detailed information on
antibodies, chemicals, reagents, and the process of histo-
logical evaluation in the current work.
Occurrence of tumor necrosis
The presence of histological tumor necrosis in the studied
HCC specimens was classified into two categories: 1,
negative or 2, positive, as previously described [25, 26]. Pa-
tients were categorized into two groups (necrosis+ and ne-
crosis− groups) according to their “positive” or “negative”
necrosis scores. In addition, the presence of liver steatosis
was categorized into four degrees: absence of steatosis (0–
5%), mild steatosis (> 5% and < 30%), moderate steatosis
(30–60%), and severe steatosis (> 60%) [33], according to
established histopathologic criteria [33].
Statistical analysis
The IBM SPSS Statistics (Version 25/Year 2017) soft-
ware program was used to perform the univariate and
Kaplan–Meier survival analyses. The chi-squared (χ2)
test was applied to determine whether there was a sig-
nificant difference between the observed frequencies in
the categorical variables (clinicopathologic characteris-
tics) in our study. The Fischer test was applied when the
number of patients in the subgroups was less than five
(n < 5) in more than 25% of cases. Survival data were an-
alyzed using the log-rank test. To investigate whether
the studied variables and biomarkers qualify as inde-
pendent prognostic factors, we performed a multivariate
analysis in a step-wise manner. Parameters that signifi-
cantly affected survival rates or showed a strong trend
for significance in the univariate analysis were entered
into a step-wise Cox regression hazard model. A differ-
ence was considered significant for p ≤ 0.05.
Results
TIE2-expressing monocytes and angiopoietins are
associated with advanced histologic grading and tumor
recurrence in patients with HCC
Typical images for monocytes/macrophages and angio-
poietins in HCC are shown in Figs. 1 and 2. The statis-
tical data of the patients is summarized in Tables 1, 2, 3,
and 4 and in the Additional file 3. In our study, the pres-
ence of TEMs was associated with enhanced incidences
of both local tumor recurrence and overall tumor recur-
rence and worse histologic differentiation of HCC
(Fig. 1a, b; Table 1). In the TEM− group, 4/19 (21.1%)
patients had an overall tumor recurrence, and in the
TEM+ group, 19/39 (48.7%) patients exhibited this fea-
ture (p = 0.043). Moreover, the presence of TEMs was
also associated with an unfavorable histologic differenti-
ation of the tumor. In the TEM+ group, 35/39 (89.7%)
patients were diagnosed with an advanced histologic
grading, whereas in the TEM− group, 12/19 (63.2%) pa-
tients had this feature (p = 0.015). In the current work,
the presence of angiopoietin-1 in the TIF was associated
with an enhanced incidence of local tumor recurrence
(p = 0.007) (Fig. 1c, d; Table 2). After liver resection for
HCC, in the ANG1high group, 6/9 (66.7%) patients expe-
rienced local tumor recurrence, whereas in the ANG1low
group, only 11/49 (22.4%) patients had this
phenomenon.
Tumor necrosis is associated with an advanced tumor
stage and TIE2-expressing monocytes in patients with
HCC
Typical images for the occurrence of tumor necrosis in
HCC are shown in Fig. 2. The statistical data of the pa-
tients is summarized in Table 3. Tumor necrosis was as-
sociated with an advanced tumor stage (tumor stage T3/
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Fig. 1 Immunohistological detection of infiltrating TIE2-expressing monocytes (TEMs), angiopoietins (left column: high density; right column: low
density) in the tumor central area (TCA) of hepatocellular carcinoma (HCC) specimens. Arrows indicate positive staining and asterisks indicate
microvessels. Scale bar, 50 μm. Therefore, the corresponding monocytes (i.e., TEMs) are visualized as cells that are double positive for CD14 and
TIE2. This positivity in the immunohistology is seen as simultaneous red and brown staining (arrows). On the other hand, microvessels (i.e.,
endothelial cells) are positive only for TIE2 and are, thus, visualized as brown reactivity only (asterisks). a High density of TIE2+ monocytes in the
TCA. HCC revealed a homogenous infiltration pattern of these cells with preference for the perivascular areas. b Low density of TIE2+ monocytes
(arrows). c High angiopoietin-1 expression. d Low angiopoietin-1 expression
Fig. 2 Detection of histologic tumor necrosis and infiltrating TIE2-expressing monocytes (TEMs) in hepatocellular carcinoma (HCC) specimens.
Arrows indicate positive staining for TEMs (simultaneous red and brown staining) and diamond signs indicate tumor necrosis. Scale bar, 50 μm. a
Tumor specimen with histological tumor necrosis. b Tumor specimen with histological tumor necrosis (diamond signs) and presence of
TEMs (arrows)
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T4; p = 0.038). In the necrosis+ group, 21/35 (60.0%) pa-
tients showed an advanced T stage, whereas in the ne-
crosis− group, only 8/23 (31.8%) patients revealed this
feature. Furthermore, tumor necrosis was associated
with intensified TEM infiltration in HCC (Fig. 2,
Table 3). In the necrosis− group, infiltrating TEMs in
TCA were detected in only 2/23 (8.7%) patients. In com-
parison, in the necrosis+ group, 12/35 (34.3%) patients
showed tumor-infiltrating TEMs (p = 0.026).
Influence on survival and prognostic significance of
angiopoietins, TIE2-expressing monocytes and tumor
necrosis in HCC patients
In the present study, TEMs and histologic tumor ne-
crosis was associated with patients’ overall survival
and recurrence-free survival after liver resection for
HCC. The Kaplan–Meier survival curves are shown in
Fig. 3. The statistical data of all patients is summa-
rized in Tables 1, 2, 3, and 4. After liver resection for
HCC, survival was decreased in patients with TEMs
in TCA (p = 0.056) when compared to patients with-
out these cells in the TCA. The overall 1-, 3-, and 5-
year survival rates were 63.3%, 42.8%, and 42.8%,
respectively, in the TEM+ group as compared to
79.6%, 77.1%, and 75.0%, respectively, in the TEM−
group (Fig. 3a). Furthermore, the presence of TEMs
in the TIF was associated with a reduced recurrence-
free survival. The 1-, 3-, and 5-year recurrence-free
survival of patients with TEMs were lower (52.0%,
43.3%, and 42.2%, respectively) as compared to pa-
tients without TEMs (83.1%, 77.9%, and 77.9%, re-
spectively) (p = 0.035) (Fig. 3b). Patients in the
necrosis− group had improved overall survival and
recurrence-free survival when compared with the ne-
crosis+ group (Fig. 3c, d; p = 0.055 and p = 0.019, re-
spectively). In addition, we analyzed whether
angiopoietins, infiltrating TEMs, and histologic tumor
necrosis could predict patient outcomes after surgery
for HCC. Using a step-wise multivariate analysis, in
addition to other established clinicopathological pa-
rameters, angiopoietin-1 and TEMs were identified as
independent prognostic factors for both overall sur-
vival and recurrence-free survival (Table 4). In our
work, the presence of liver steatosis was not
Table 1 Association of the presence of TIE2-expressing
monocytes (TEMs) at the tumor-infiltrating front (TIF) with
clinicopathological characteristics of patients with hepatocellular
carcinoma (HCC) as determined by the chi-squared (χ2) test
Variable TEM+/TIF TEM−/TIF p
No. of patients 39 19
Patient- and tumor-related variables
Patient age, years 0.094
≤ 60 17 (43.6%) 4 (21.1%)
> 60 22 (56.4%) 15 (78.9%)
Gender 0.029
Female 27 (69.2%) 18 (94.7%)
Male 12 (30.8%) 1 (5.3%)
Multiple tumor nodules 0.862
Positive 9 (23.1%) 4 (21.1%)
Negative 30 (76.9%) 15 (78.9%)
Tumor size, mm 0.319
≤ 50 6 (15.4%) 5 (26.3%)
> 50 33 (84.6%) 14 (73.7%)
Angioinvasion 0.113
Positive 23 (59.0%) 7 (36.8%)
Negative 16 (41.0%) 12 (63.2%)
Lymphangiosis carcinomatosa 0.727
Positive 12 (30.8%) 5 (26.3%)
Negative 27 (69.2%) 14 (73.7%)
Histologic differentiation 0.015
Well 4 (10.3%) 7 (36.8%)
Moderate/poor 35 (89.7%) 12 (63.2%)
Pathologic T stage 0.631
T1/T2 19 (48.7%) 10 (55.6%)
T3/T4 20 (51.3%) 8 (44.4%)
Pathologic N stage 0.315
Positive 2 (5.1%) 0 (0.0%)
Negative 37 (94.9%) 19 (100.0%)
Operative variables
R status 0.464
Positive 7 (17.9%) 2 (10.5%)
Negative 32 (82.1%) 17 (89.5%)
Variables of patient outcome
Local tumor recurrence 0.005
Positive 16 (41.0%) 1 (5.3%)
Negative 23 (59.0%) 18 (94.7%)
Overall tumor recurrence 0.043
Positive 19 (48.7%) 4 (21.1%)
Negative 20 (51.3%) 15 (78.9%)
Metastases 0.667
Positive 8 (20.5%) 3 (15.8%)
Table 1 Association of the presence of TIE2-expressing
monocytes (TEMs) at the tumor-infiltrating front (TIF) with
clinicopathological characteristics of patients with hepatocellular
carcinoma (HCC) as determined by the chi-squared (χ2) test
(Continued)
Variable TEM+/TIF TEM−/TIF p
Negative 31 (79.5%) 16 (84.2%)
The Fischer test was applied when the number of patients in the subgroups
was less than five (n < 5) in more than 25% of cases
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associated with patient outcomes following resection.
The Additional file 3 provides a synopsis concerning
the results with liver steatosis.
Discussion
In our work, the tissue densities of angiopoietins and
angiopoietin receptor-bearing monocytes/macrophages
as well as the occurrence of histologic tumor necrosis in
specimens of HCC patients were associated with clinico-
pathologic characteristics and patient survival. The main
findings were as follows: (1) angiopoietins and infiltrat-
ing TEMs were associated with metastatic and recurrent
disease; (2) the presence of tumor necrosis was associ-
ated with an advanced tumor stage and associated with
TEM frequency; and (3) necrosis and TEMs exerted a
pernicious influence on patient survival.
In this study, we demonstrated that high angiopoietin
expression and the presence of TEMs was associated with
recurrent and metastatic HCC. These results are in accord-
ance with previously published results on HCC and other
hepatobiliary tumors, which delineate the negative impact of
infiltrating monocytes/macrophages on patient survival and
outcome [34–37]. Angiopoietins represent a potential prog-
nostic biomarker of therapeutic responsiveness to anticancer
Table 2 Association of relative angiopoietin-1 (ANG1)
expression at the tumor-infiltrating front (TIF) or central area
(TCA) with clinicopathological characteristics of the patients
with hepatocellular carcinoma (HCC) as determined by the chi-
squared (χ2) test
Variable ANG1 high/TIF ANG1 low/TIF p
No. of patients 9 49
Patient- and tumor-related variables
Patient age, years 0.342
≤ 60 2 (22.7%) 19 (38.8%)
> 60 7 (77.8%) 30 (61.2%)
Gender 0.079
Female 9 (100.0%) 36 (73.5%)
Male 0 (00.0%) 13 (26.5%)
Multiple tumor nodules 0.376
Positive 1 (1.1%) 12 (24.5%)
Negative 8 (88.9%) 37 (75.5%)
Tumor size, mm 0.114
≤ 50 0 (00.0%) 11 (22.4%)
> 50 9 (100.0%) 38 (77.6%)
Angioinvasion 0.634
Positive 4 (44.4%) 26 (53.1%)
Negative 5 (55.6%) 23 (46.9%)
Histologic differentiation 0.786
Well 2 (22.2%) 9 (18.4%)
Moderate/poor 7 (77.8%) 40 (81.6%)
Pathologic T stage 0.079
T1/T2 7 (77.8%) 22 (45.8%)
T3/T4 2 (22.2%) 27 (54.2%)
Pathologic N stage 0.537
Positive 0 (00.0%) 2 (4.1%)
Negative 9 (100.0%) 47(95.9%)
TEMs in TIF 0.132
Positive 8 (88.9%) 31 (63.3%)
Negative 1 (11.1%) 18 (36.7%)
Operative variables
R status 0.691
Positive 1 (11.1%) 8 (16.3%)
Negative 8 (88.9%) 41 (83.7%)
Variables of patient outcome
Local tumor recurrence 0.007
Positive 6 (66.7%) 11 (22.4%)
Negative 3 (33.3%) 38 (77.6%)
Overall tumor recurrence 0.072
Positive 6 (66.7%) 17 (34.7%)
Negative 3 (33.3%) 32 (65.3%)
Metastases 0.513
Table 2 Association of relative angiopoietin-1 (ANG1)
expression at the tumor-infiltrating front (TIF) or central area
(TCA) with clinicopathological characteristics of the patients
with hepatocellular carcinoma (HCC) as determined by the chi-
squared (χ2) test (Continued)
Variable ANG1 high/TIF ANG1 low/TIF p
Positive 1 (1.1%) 10 (20.4%)
Negative 8 (88.9%) 39 (79.6%)
Variable ANG1 high/TCA ANG1 low/TCA p
No. of patients 12 46
Patient- and tumor-related variables
TEMs in TCA 0.111
Positive 5 (41.7%) 9 (19.6%)
Negative 7 (58.3%) 37 (80.4%)
TEMs in TIF 0.182
Positive 10 (83.3%) 29 (63.0%)
Negative 2 (16.7%) 17 (36.0%)
Angioinvasion 0.245
Positive 8 (66.7%) 22 (47.8%)
Negative 4 (33.3%) 24 (52.2%)
Variables of patient outcome
Metastases 0.024
Positive 5 (41.7%) 6 (13.0%)
Negative 7 (58.3%) 40 (87.0%)
The Fischer test was applied when the number of patients in the subgroups
was less than five (n < 5) in more than 25% of cases
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treatments, including immunotherapy using immunomodu-
latory agents [38]. The activation of the angiopoietin-TIE2
axis could be a potent tumor escape mechanism from anti-
angiogenic treatment. Novel data implicates that, in
HCC, angiopoietins are co-expressed with VEGF
and transiently decrease during the window of
normalization and return to baseline levels after
anti-VEGF therapy [38]. Tumor-derived VEGF can
increase the tumor expression of angiopoietins and
promote metastases, suggesting that interactions be-
tween these angiogenic pathways promote tumor
progression [39]. Furthermore, several preclinical
studies have shown that monocytes/macrophages,
and especially angiopoietin receptors-bearing TEMs,
contribute to tumor neoangiogenesis in mouse
tumor models [40]. Therefore, these monocytes/
macrophages may exert potent abilities to enhance
the extent of tumor neoangiogenesis and progres-
sion to increased malignancy in patients with HCC.
These findings suggest that angiopoietin signaling
may foster the invasion of monocytes/macrophages,
resulting in deleterious effects in HCC; however,
further studies are needed to elucidate the possible
functional mechanisms and help conceptualize novel
Table 3 Association of histologic tumor necrosis with
clinicopathological characteristics of the patients with
hepatocellular carcinoma (HCC) as determined by the chi-
squared (χ2) test
Variable Necrosis+ Necrosis p
No. of patients 35 23
Patient- and tumor-related variables
Patient age, years 0.707
≤ 60 12 (34.3%) 9 (39.1%)
> 60 23 (65.7%) 14 (60.9%)
Gender 0.920
Female 27 (77.1%) 18 (78.3%)
Male 8 (22.9%) 5 (21.7%)
Multiple tumor nodules 0.587
Positive 7 (20.0%) 6 (26.1%)
Negative 28 (80.0%) 17 (73.9%)
Tumor size, mm 0.001
≤ 50 2 (5.7%) 9 (39.1%)
> 50 33 (94.3%) 14 (60.9%)
Angioinvasion 0.120
Positive 21 (60.0%) 9 (39.1%)
Negative 14 (40.0%) 14 (60.9%)
Lymphangiosis carcinomatosa 0.304
Positive 12 (34.3%) 5 (21.7%)
Negative 23 (65.7%) 18 (78.3%)
Histologic differentiation 0.262
Well 5 (14.3%) 6 (26.1%)
Moderate/poor 30 (85.7%) 17 (73.9%)
Pathologic T stage 0.038
T1/T2 14 (40.0%) 15 (68.2%)
T3/T4 21 (60.0%) 8 (31.8%)
Pathologic N stage 0.076
Positive 0 (00.0%) 2 (8.7%)
Negative 35 (100.0%) 21 (91.3%)
TEMs in TCA 0.026
Positive 12 (34.3%) 2 (8.7%)
Negative 23 (65.7%) 21 (91.3%)
TEMs in TIF 0.402
Positive 25 (71.4%) 14 (60.9%)
Negative 10 (28.6%) 9 (39.1%)
Angiopoietin-1 in TCA 0.149
Positive 3 (8.6%) 0 (00.0%)
Negative 32 (91.4%) 23 (100.0%)
Angiopoietin-1 in TIF 0.245
Positive 28 (80.0%) 21 (91.3%)
Negative 7 (20.0%) 2 (8.7%)
Angiopoietin-2 in TCA 0.818
Table 3 Association of histologic tumor necrosis with
clinicopathological characteristics of the patients with
hepatocellular carcinoma (HCC) as determined by the chi-
squared (χ2) test (Continued)
Variable Necrosis+ Necrosis p
Positive 2 (5.7%) 1 (4.3%)
Negative 33 (94.3%) 22 (95.7%)
Angiopoietin-2 in TIF 0.326
Positive 1 (2.9%) 2 (8.7%)
Negative 34 (97.1%) 21 (91.3%)
Operative variables
R status 0.245
Positive 7 (20.0%) 2 (8.7%)
Negative 28 (80.0%) 21 (91.3%)
Variables of patient outcome
Local tumor recurrence 0.662
Positive 11 (31.4%) 6 (26.1%)
Negative 24 (68.6%) 17 (73.9%)
Overall tumor recurrence 0.087
Positive 17 (48.6%) 6 (26.1%)
Negative 18 (51.4%) 17 (73.9%)
Metastases 0.103
Positive 9 (25.7%) 2 (8.7%)
Negative 26 (74.3%) 21 (91.3%)
The Fischer test was applied when the number of patients in the subgroups
was less than five (n < 5) in more than 25% of cases
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checkpoint inhibitor targets for cancer
immunotherapy.
HCC is a highly vascularized tumor and the recurrent
disease remains a major clinical obstacle and defines the
outcome of the patients receiving curative therapy. In
the current work, we provide data that could be used to
identify subgroups of patients with advantageous or
deleterious HCC characteristics, respectively. Such a per-
sonalized approach may have a useful clinical implica-
tion in order to improve the individualized risk
stratification after surgery and curative treatments. This
translates ultimately into more intensified and purpose-
ful aftercare of patients with HCC at high risk for
adverse outcomes. De Palma et al. were the first to re-
port on the significance of TEMs in regard to tumor
neoangiogenesis [18]. In the clinical setting, Matsubara
et al. reported first on the importance of TEMs in hu-
man blood and associated their presence with tumor
neoangiogenesis, recurrence, and patient survival rates
[41]. Consequently, our group reported on the prognos-
tic value of TEMs and histologic tumor necrosis in other
hepatobiliary tumors [19–21, 25, 26]. Here, we showed
that tumor necrosis and the presence of TEMs and
angiopoietins were associated with an advanced HCC. In
the current work, tumor necrosis was also associated
with TEM density in HCC. These characteristics of the
Table 4 Multivariate analysis of prognostic factors in patients with hepatocellular carcinoma (HCC) conducted in a step-wise manner
Variable Category Odds ratio p Confidence interval
Overall survival
Distant metastases Negative (n = 47) 0.605 0.602 0.091–4.011
Positive (n = 11)
Overall tumor recurrence Negative (n = 35) 1.828 0.272 0.623–5.368
Positive (n = 23)
Angioinvasion Negative (n = 28) 0.286 0.040 0.086–0.945
Positive (n = 30)
Lymphangiosis carcinomatosa Negative (n = 41) 1.700 0.330 0.585–4.940
Positive (n = 17)
T status T1&T2 (n = 29) 18.606 0.001 3.397–101.904
T3&T4 (n = 29)
Angiopoietin-1 in TCA Negative (n = 55) 4.859 0.021 1.274–18.537
Positive (n = 3)
TEMs in TCA Negative (n = 44) 2.837 0.051 0.997–8.071
Positive (n = 14)
Recurrence-free survival
R status Negative (n = 49) 4.346 0.061 0.936–20.174
Positive (n = 9)
T status T1&T2 (n = 29) 11.213 0.0001 2.997–41.957
T3&T4 (n = 29)
Angioinvasion Negative (n = 28) 0.458 0.122 0.170–1.234
Positive (n = 30)
Lymph node involvement Negative (n = 56) 0.311 0.255 0.042–2.322
Positive (n = 56)
TEMs in TCA Negative (n = 44) 0.391 0.083 0.135–1.132
Positive (n = 14)
TEMs in TIF Negative (n = 19) 3.677 0.049 1.1007–13.430
Positive (n = 39)
Angiopoietin-1 in TIF Negative (n = 9) 0.102 0.001 0.028–0.380
Positive (n = 49)
Angiopoietin-1 in TCA Negative (n = 55) 20.920 0.004 2.620–167.067
Positive (n = 3)
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tumor microenvironment also affected overall survival
and recurrence-free survival of the patients. Thus, we
propose a coherent construct comprising tumor necro-
sis, neoangiogenesis, and associated TEMs as an attract-
ive diagnostic modality prognosticating the outcome of
HCC patients following radical surgery.
The clinical translation of novel immunologic aspects
of the tumor biology represents an urgent unmet need.
In addition, a major clinical problem is the lack of adju-
vant treatment strategies in patients with advanced HCC
[34]. Novel experimental techniques demonstrated high
efficacy in visualization of important localized sites of
the tumor microenvironment and related tumor necro-
sis. Moreover, these approaches offer the possibility for
nanoparticles uptake and consequent clinical imaging of
monocytes/macrophages in the vicinity of the tumor, as
well. Aghighi et al. established a novel MRI-based mo-
dality for selective visualization of the tumor central area
and the infiltrating margin that is adjacent to normal
non-cancerous tissues [42]. In this setting, the utilization
Fig. 3 Association of TIE2-expressing monocytes (TEMs), tumor necrosis, and angiopoietins with patient survival using the Kaplan–Meier survival
analysis. a Overall survival after hepatocellular carcinoma (HCC) surgery in relation to presence or absence of TEMs in the tumor central area
(TCA). b Recurrence-free survival after HCC surgery in relation to presence or absence of TEMs in the tumor-infiltrating front (TIF). c Survival after
HCC surgery in relation to presence or absence of histologic tumor necrosis. d Recurrence-free survival after HCC surgery in relation to presence
or absence of histologic tumor necrosis. e Overall survival after HCC surgery in relation to low or high angiopoietin expression in the TCA. f
Recurrence-free survival after HCC surgery in relation to low or high angiopoietin expression in the TCA
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of ultra-small superparamagnetic iron oxide nanoparti-
cles in ferumoxytol-enhanced MRI provides an oppor-
tunity to better characterize the extra- and intracellular
compartments of solid tumors, corresponding TAMs,
and formation of necrosis in the tumor microenviron-
ment, which is a novel diagnostic tool with a high sensi-
tivity and potential for immediate clinical translation
[42, 43]. Moreover, a novel tumor necrosis therapy
(TNT), which provides a new and promising therapeutic
anticancer modality, has been recently described, as well
[44]. Through radiolabeled necrosis avid compounds
(i.e., small molecules with a high affinity for and long-
lasting retention in necrotic tissues), tumor necrosis can
be a carrier of therapeutic radionuclides [45–47].
Conclusions
In conclusion, formation of histologic tumor necrosis is
associated with the intratumoral density of invading an-
giogenic TEMs of HCC patients. Furthermore, the tumor
necrosis–TEM–angiopoietin axis was associated with dis-
ease recurrence, advanced tumor stage, and reduced sur-
vival after radical surgery in these patients. Thus, our data
may indicate the tumor necrosis–TEM–angiopoietin axis
is a novel checkpoint target in tumor immunotherapy
and, at the same time, provides potent anti-angiogenesis
modalities in advanced HCC. However, some limitations
of the current study should be taken into account. The
small number of cases in the different subgroups remains
the main drawback. On the other hand, our work incorpo-
rated no functional studies and remains a descriptive
study. Therefore, further research encompassing larger pa-
tient populations with focus on functional assays and
mechanistic links is urgently needed. This will deliver a
deeper biological insight into possible mechanistic mo-
lecular pathways might help develop novel immunologic
checkpoint inhibitor targets for hepatic malignancies.
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